No Data
No Data
No Data
No Data
No Data
Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties
TipRanksApr 26 14:11
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in n
BioXcel TherapeuticsApr 25 12:00
BioXcel Therapeutics Announces Late-Breaking Abstract On Preliminary Findings From Phase 2 Investigator-Sponsored Trial Of BXCL701 And KEYTRUDA In Metastatic Pancreatic Ductal Adenocarcinoma Selected For Presentation At 2024 ASCO Annual Meeting
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ETTrial being led by Georgetown University's Lombardi Comprehensive Cancer CenterNEW HAVEN, Conn., April 24, 2024 (GLOBE N
BenzingaApr 24 22:33
HC Wainwright & Co. : The BioXcel Therapeutics (BTAI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
HC Wainwright & Co. : The BioXcel Therapeutics (BTAI.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $10.00.
Zhitong FinanceApr 23 18:31
HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $10 price target.
BenzingaApr 23 18:28
BioXcel Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 250.88% HC Wainwright & Co. → $10 Reiterates Buy → Buy 03/18/2024 285.96% HC Wainwright & Co. →
BenzingaApr 23 18:27
No Data
No Data